Clinical Trial

Clario Announces Completion of Acquisition of WCG’s eCOA Business

Clario strengthens its leadership in digital endpoint data collection with the acquisition of WCG's eCOA business, enhancing support for neuroscience…

8 months ago

Caresyntax and The Jacobs Institute Announce Strategic Collaboration to Advance Surgical Insights and Real-World Evidence Generation

BUFFALO, N.Y., May 6, 2025 /PRNewswire/ -- Caresyntax Corporation, a leader in surgical data integration and intelligence, and The Jacobs Institute,…

8 months ago

Tech That Listens, Learns, and Diagnoses: AI’s Breakout Moment in Healthcare

USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 6, 2025 /PRNewswire/ -- Healthcare…

8 months ago

DCN Dx Launches Redesigned Website to Improve Access to Resources, Showcase Team

CARLSBAD, Calif., May 6, 2025 /PRNewswire/ -- DCN Dx, a specialist in lateral flow diagnostics development, manufacturing, and IVD regulatory…

8 months ago

LiveKidney Enrolls First Patient in Phase I/IIa Clinical Trial to Assess LK-SC001 for Treatment of Lupus

U.S. Study Assessing Safety and Efficacy of Umbilical Cord-Derived Mesenchymal Stromal Cells (UC-MSCs) Transformative Therapy to Improve Kidney Function and…

8 months ago

Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology

LAS VEGAS, May 6, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ('Avant' or the 'Company'), and its JV partner, Ainnova…

8 months ago

BrainStorm to Present Biomarker Insights Supporting NurOwn’s Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit

Presentation of biomarker findings from cerebrospinal fluid analysesWorkshop on adaptive and decentralized ALS trial designPanel on clinical trial access and the…

8 months ago

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

Annamycin has the potential to be safer and more effective than current prescribed anthracyclines to treat serious, hard-to-treat cancers Ongoing…

8 months ago

Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and…

8 months ago

Candel Therapeutics to Present at Upcoming Investor Conferences

NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage…

8 months ago